{"title":"玻璃体内地塞米松植入治疗糖尿病性黄斑水肿后的黄斑厚度波动和视力效果。","authors":"Héloïse Torres-Villaros, Rhyme Timoumi, Franck Fajnkuchen, Arnaud Klokner, Audrey Giocanti-Aurégan","doi":"10.1097/IAE.0000000000004213","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To assess macular thickness fluctuations and their association with visual acuity (VA) outcomes in eyes with diabetic macular edema (DME) treated with intravitreal dexamethasone (DEX) implant.</p><p><strong>Methods: </strong>The standard deviation (SD) of all post-baseline central subfield thicknesses (CST) recorded over a 12-month period after the first injection of DEX implant was used to quantify CST fluctuations. Linear regression models were used to identify factors associated with the VA at 12 months (measured with the Early Treatment of Diabetic Retinopathy Study (ETDRS) score), and predictors of CST SD.</p><p><strong>Results: </strong>A retrospective review of 80 eyes of 80 patients treated with DEX implant for DME revealed a CST SD of 75.3 ± 50.3 μm. The CST SD was negatively associated with the VA at 12 months (-7.7 EDTRS letters for each 100-µm increase in CST SD, p=0.01), while changes in CST from baseline did not show any significant association. Eyes were stratified into quartiles based on the CST SD and a difference by -14.2 letters in VA at 12 months was observed between the first and fourth quartiles (p <0.001). Significant predictors of CST SD included the baseline VA (-12.0 μm for each 10-letter increase, p=0.02), and the number of DEX injections received (n=17.1, p=0.03).</p><p><strong>Conclusion: </strong>Greater fluctuations in retinal thickness were found to be associated with poorer visual outcomes in eyes with DME treated with DEX implant. Analyzing the CST SD could be a more predictive indicator of visual prognosis than individual measurements of the CST.</p>","PeriodicalId":54486,"journal":{"name":"Retina-The Journal of Retinal and Vitreous Diseases","volume":null,"pages":null},"PeriodicalIF":2.3000,"publicationDate":"2024-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Macular thickness fluctuations and visual acuity outcomes after intravitreal dexamethasone implant for diabetic macular edema.\",\"authors\":\"Héloïse Torres-Villaros, Rhyme Timoumi, Franck Fajnkuchen, Arnaud Klokner, Audrey Giocanti-Aurégan\",\"doi\":\"10.1097/IAE.0000000000004213\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>To assess macular thickness fluctuations and their association with visual acuity (VA) outcomes in eyes with diabetic macular edema (DME) treated with intravitreal dexamethasone (DEX) implant.</p><p><strong>Methods: </strong>The standard deviation (SD) of all post-baseline central subfield thicknesses (CST) recorded over a 12-month period after the first injection of DEX implant was used to quantify CST fluctuations. Linear regression models were used to identify factors associated with the VA at 12 months (measured with the Early Treatment of Diabetic Retinopathy Study (ETDRS) score), and predictors of CST SD.</p><p><strong>Results: </strong>A retrospective review of 80 eyes of 80 patients treated with DEX implant for DME revealed a CST SD of 75.3 ± 50.3 μm. The CST SD was negatively associated with the VA at 12 months (-7.7 EDTRS letters for each 100-µm increase in CST SD, p=0.01), while changes in CST from baseline did not show any significant association. Eyes were stratified into quartiles based on the CST SD and a difference by -14.2 letters in VA at 12 months was observed between the first and fourth quartiles (p <0.001). Significant predictors of CST SD included the baseline VA (-12.0 μm for each 10-letter increase, p=0.02), and the number of DEX injections received (n=17.1, p=0.03).</p><p><strong>Conclusion: </strong>Greater fluctuations in retinal thickness were found to be associated with poorer visual outcomes in eyes with DME treated with DEX implant. Analyzing the CST SD could be a more predictive indicator of visual prognosis than individual measurements of the CST.</p>\",\"PeriodicalId\":54486,\"journal\":{\"name\":\"Retina-The Journal of Retinal and Vitreous Diseases\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2024-08-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Retina-The Journal of Retinal and Vitreous Diseases\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1097/IAE.0000000000004213\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"OPHTHALMOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Retina-The Journal of Retinal and Vitreous Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/IAE.0000000000004213","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
Macular thickness fluctuations and visual acuity outcomes after intravitreal dexamethasone implant for diabetic macular edema.
Purpose: To assess macular thickness fluctuations and their association with visual acuity (VA) outcomes in eyes with diabetic macular edema (DME) treated with intravitreal dexamethasone (DEX) implant.
Methods: The standard deviation (SD) of all post-baseline central subfield thicknesses (CST) recorded over a 12-month period after the first injection of DEX implant was used to quantify CST fluctuations. Linear regression models were used to identify factors associated with the VA at 12 months (measured with the Early Treatment of Diabetic Retinopathy Study (ETDRS) score), and predictors of CST SD.
Results: A retrospective review of 80 eyes of 80 patients treated with DEX implant for DME revealed a CST SD of 75.3 ± 50.3 μm. The CST SD was negatively associated with the VA at 12 months (-7.7 EDTRS letters for each 100-µm increase in CST SD, p=0.01), while changes in CST from baseline did not show any significant association. Eyes were stratified into quartiles based on the CST SD and a difference by -14.2 letters in VA at 12 months was observed between the first and fourth quartiles (p <0.001). Significant predictors of CST SD included the baseline VA (-12.0 μm for each 10-letter increase, p=0.02), and the number of DEX injections received (n=17.1, p=0.03).
Conclusion: Greater fluctuations in retinal thickness were found to be associated with poorer visual outcomes in eyes with DME treated with DEX implant. Analyzing the CST SD could be a more predictive indicator of visual prognosis than individual measurements of the CST.
期刊介绍:
RETINA® focuses exclusively on the growing specialty of vitreoretinal disorders. The Journal provides current information on diagnostic and therapeutic techniques. Its highly specialized and informative, peer-reviewed articles are easily applicable to clinical practice.
In addition to regular reports from clinical and basic science investigators, RETINA® publishes special features including periodic review articles on pertinent topics, special articles dealing with surgical and other therapeutic techniques, and abstract cards. Issues are abundantly illustrated in vivid full color.
Published 12 times per year, RETINA® is truly a “must have” publication for anyone connected to this field.